RecruitingPhase 1Phase 2NCT07246278

Celecoxib in Parkinson Disease as Adjuvant Therapy

Evaluating Safety and Efficacy of Celecoxib in Patients With PD.

Sponsor

Tanta University

Enrollment

80 participants

Start Date

Nov 20, 2025

Study Type

INTERVENTIONAL

Conditions

Parkinson Disease

Summary

Parkinson's disease (PD) is a chronic neurodegenerative disease clinically characterized by bradykinesia, hypokinesia, rigidity, resting tremor, and postural instability. These motor manifestations are attributed to the degeneration and selective loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc), leading to a dopamine (DA) deficiency in the striatum. Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD

Eligibility

Min Age: 50 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether adding celecoxib (an anti-inflammatory pain medication, commonly known as a COX-2 inhibitor) to standard Parkinson's disease treatment helps slow disease progression or improve symptoms. Inflammation is thought to contribute to Parkinson's, and celecoxib reduces that inflammation. **You may be eligible if...** - You are 18 or older - You have been diagnosed with Parkinson's disease - You are male or female **You may NOT be eligible if...** - You are breastfeeding - You have significant liver or kidney disease - You abuse alcohol or drugs - You have a known allergy to celecoxib, sulfonamides, or aspirin/NSAIDs - You have a history of stomach ulcers or gastrointestinal bleeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLevodopa Carbidopa

Carbidopa/levodopa is the combination of the two medications carbidopa and levodopa. It is primarily used to manage the symptoms of Parkinson's disease

DRUGCelecoxib 200mg

Celecoxib, is a selective cyclooxygenase-2 inhibitor. Prostaglandins (PG) are produced from arachidonic acid by the constitutively expressed cyclooxygenase-1(COX-1)